We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
11 Aug 2021 - 15 Aug 2021
Virtual Venue
16 Aug 2021 - 26 Aug 2021
Virtual Venue

Optoacoustic Technology Enhances Breast Cancer Diagnostics

By MedImaging International staff writers
Posted on 18 Feb 2021
Print article
Image: A novel breast imaging system fuses optoacoustics and ultrasound (Photo courtesy of Seno Medical)
Image: A novel breast imaging system fuses optoacoustics and ultrasound (Photo courtesy of Seno Medical)
An innovative breast cancer imaging system combines ultrasound (US) and optoacoustics (OA) to help differentiate between benign and malignant breast lesions.

The Seno Medical Instruments (Seno; San Antonio, TX, USA) Imagio OA/US system is indicated for use by trained and qualified healthcare providers to evaluate palpable and non-palpable breast abnormalities in adult patients who are referred for diagnostic imaging breast work-up, following clinical presentation or other imaging examinations such as screening mammography. Imagio uses laser optics and grayscale ultrasound to provide fused, functional, and anatomical breast imaging.

The OA images provide a unique blood map in and around breast masses, while US provides a traditional anatomical image. Through the appearance (or absence) of two hallmark cancer indicators, angiogenesis and deoxygenation, radiologists can confirm or rule out malignancy, without necessitating the use of ionizing radiation (x-rays) or contrast agents. In addition to imaging enhancement, Imagio also includes SenoGram, an artificial intelligence (AI) physician decision support tool that aids in the interpretation of the new images.

“Optimizing the diagnosis of breast masses requires a combination of very high sensitivity, over 98%, while simultaneously maximizing specificity and minimizing false positives and biopsies of benign masses,” said A. Thomas Stavros, MD, chief medical officer of Seno. “Other modalities have reported improvements in specificity, but these have often come at the expense of the desired high sensitivity.”

Optoacoustic imaging is an imaging modality that uses non-ionizing laser pulsing of biological tissues to initiate a photoacoustic effect, in which part of the energy is absorbed and converted into heat, leading to a transient thermoelastic expansion, which generates a wideband ultrasonic emission. As the optical absorption is closely associated with physiological properties--such as hemoglobin concentration and oxygen saturation--the photoacoustic signal, detected by ultrasonic transducers, is proportional to local energy deposition.

Related Links:
Seno Medical Instruments


Print article
CIRS
Radcal

Channels

Industry News

view channel
Illustration

Global AI in Medical Diagnostics Market Projected to Reach USD 3.87 Billion by 2025

The global AI in medical diagnostics market is projected to grow at a CAGR of 50.2% from USD 505 million in 2020 to USD 3.87 billion by 2025, driven primarily by government initiatives to increase adoption... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.